Nanjing Leads Biolabs Co Ltd
Company Profile
Business description
Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. It has one Core Product, LBL-024 (registrational-stage PD-L1 and 4-1BB dual-targeting bispecific antibody), which it is evaluating for its therapeutic potential in extra-pulmonary neuroendocrine carcinoma both as monotherapy for patients who have received at least three prior lines of therapy and part of combination therapy as first-line treatment (1L), as well as in small cell lung cancer as 1L treatment, biliary tract cancer as 1L/1L+ treatment, non-small cell lung cancer as 1L/1L+ treatment, and other solid tumors in patients who have received at least two prior lines of therapy.
Contact
18E, Jialingjiang Street
Floor 8, Building 03
Jiangsu
Nanjing210019
CHNT: +86 2558862889
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
192
Stocks News & Analysis
stocks
Jet fuel price spike weighing on Australian airline profits
stocks
US utilities stocks keep rallying as investors bet on power demand growth
stocks
What did Morningstar subscribers buy and sell during March?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,180.00 | 30.20 | -0.33% |
| CAC 40 | 8,327.86 | 91.88 | 1.12% |
| DAX 40 | 24,044.22 | 301.78 | 1.27% |
| Dow JONES (US) | 48,535.99 | 317.74 | 0.66% |
| FTSE 100 | 10,609.06 | 26.10 | 0.25% |
| HKSE | 26,076.95 | 204.63 | 0.79% |
| NASDAQ | 23,639.08 | 455.35 | 1.96% |
| Nikkei 225 | 58,162.84 | 285.45 | 0.49% |
| NZX 50 Index | 13,084.30 | 67.04 | 0.52% |
| S&P 500 | 6,967.38 | 81.14 | 1.18% |
| S&P/ASX 200 | 8,977.00 | 34.40 | -0.38% |
| SSE Composite Index | 4,036.91 | 10.28 | 0.26% |